Petrie Flom: Looking Forward February 7, 2017

Panelist: Bob Langer

Biologics present unique delivery challenges

• Small molecules vs biologics • Unique challenges for biologics

• Thick solution requires large volume doses • Inherently less stable than small molecules

• Approaches to improve dosing

• Drug-based • Change the drug itself, making a new drug

• Delivery-based • Oral with additives to increase absorption • Oral - to be more constant • Topical with additives to increase skin permeability • Injectable – to last for a long time • Local – to reduce toxicity

• Not all work for biologics • Need unique solutions designed for biologics

• New “biobetter” technology

• Additives thin drug solution • Enable reduced dose volume • Facilitate rapid home delivery • Use with biosimilars and other biologics

http://drexelmedicine.org/patient-services/rheumatology/services/ http://www.huffingtonpost.com/2013/11/22/h5n1-bird-flu-vaccine-fda_n_4326148.html

Small molecule Biologic

Hospital infusion Injection

Delivery-based solutions are broadly beneficial

Patients Providers Industry Reduced administration costs

Improved access and convenience

Increased compliance

Improved efficacy

No risks from drug development

Faster to market than developing a new drug

Platform technology

Need policy in place to support all players before products reach market

Improved safety